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patient benefit remain unclear. Following a genome-wide siRNA screen, we identified the oncogenic tran-
scription factor Myc as a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with cell
fate, we show that Myc sensitizes cells to mitotic blockers and agents that accelerate mitotic progression.
Myc achieves this by upregulating a cluster of redundant pro-apoptotic BH3-only proteins and suppressing
pro-survival Bcl-xL. Gene expression analysis of breast cancers indicates that taxane responses correlate
positively with Myc and negatively with Bcl-xL. Accordingly, pharmacological inhibition of Bcl-xL restores
apoptosis in Myc-deficient cells. These results open up opportunities for biomarkers and combination ther-
apies that could enhance traditional and second-generation antimitotic agents.INTRODUCTION
Antimitotic drugs are frontline treatments for breast, ovarian, and
lung cancer, as well as various hematological malignancies (Du-
montet and Jordan, 2010). These drugs bind tubulin and inhibit
microtubule dynamics, and although many cancers initially
respond well, some are intrinsically resistant and others acquire
resistance (Murray et al., 2012). Predicting which cancers will
respond is hampered by our limited understanding of the molec-
ular mechanisms responsible for patient benefit (Gascoigne and
Taylor, 2009; Weaver, 2014). At high concentrations, antimitotic
drugs disrupt spindle assembly, leading to mitotic arrest by
persistent activation of the spindle assembly checkpoint (SAC)
(Lara-Gonzalez et al., 2012). SAC activation blocks the anaphase
promoting complex/cyclosome (APC/C), thereby preventing
ubiquitination and degradation of cyclin B1, in turn maintainingSignificance
Antimitotic agents such as the taxanes are used widely to treat
new generation of inhibitors that disrupt mitosis without affecti
targeting mitotic kinesins and mitotic kinases. However, we sti
cell fate in response to mitotic disruption. Here we show that M
breast, ovarian, lung, and colon cancer cells to drugs that bo
Moreover, we show that Myc promotes both p53-independent
Our results raise opportunities to explore biomarkers and comthe mitotic state. Following prolonged arrest, cells either die in
mitosis or undergo ‘‘slippage,’’ returning to interphase without
completing cell division (Brito and Rieder, 2006). Following slip-
page, p53-dependent post-mitotic responses then induce cell
cycle arrest, senescence, or apoptosis (Rieder and Maiato,
2004). At lower taxol concentrations, the SAC becomes satis-
fied, allowing cells to progress through mitosis, albeit with spin-
dle abnormalities and chromosome segregation errors (Zasadil
et al., 2014). Bypassing both death in mitosis (DiM) and post-
mitotic responses can fuel chromosome instability and taxane
resistance (A’Hern et al., 2013).
The competing-networks model helps explain whether a
cell either dies in mitosis or undergoes slippage (Gascoigne and
Taylor, 2008). According to thismodel, two independent networks
dictate mitotic cell fate, one slowly generating a death signal, the
other slowly degrading cyclin B1, leading to slippage. During avarious cancers. To address limitations with these agents, a
ngmicrotubule dynamics is being evaluated, including drugs
ll have limited understanding of the mechanisms that dictate
yc drives expression of an apoptotic network that sensitizes
th activate and override the spindle assembly checkpoint.
death inmitosis and p53-dependent post-mitotic responses.
bination therapies aimed at enhancing antimitotic efficacy.
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Figure 1. A Genome-wide siRNA Screen for Regulators of Mitotic
Cell Fate
(A) Rationale for the screen based on the competing-networks model.
(B) Timeline of siRNA transfection procedure.
(C) Scatterplot of mitotic index at 24 hr against viability at 48 hr.
See also Figure S1 and Tables S1 and S2.prolonged arrest, these networks work in opposite directions:
while cell death signals become stronger, cyclin B1 levels slowly
fall due to incomplete penetrance of SAC-mediated APC/C inhibi-
tion (Brito and Rieder, 2006). Both networks have thresholds and
the fate of the cell is dictated by which threshold is breached first.
Whereas our understanding of the mechanisms regulating cyclin
B1 degradation is well advanced, less is known about death in
mitosis. It involves the intrinsic apoptosis pathway; however,
how this is regulatedduringmitosis is unclear (TophamandTaylor,
2013). The nature of the apoptotic trigger is also unclear, but DNA
damage seems a likely candidate, with one source being partial
activation of caspase-activated DNase (CAD), caused by cyto-
chrome c leakage frommitochondria (Orth et al., 2012). A second
source is telomere deprotection, driven by the mitotic kinase
AuroraB (Hayashi et al., 2012). In light of our limited understanding
regarding the mechanisms responsible for apoptosis during a
mitotic arrest, we adopted an unbiased approach and screened
a genome-wide library for siRNAs that suppress taxol-induced
cell death. To define how genes identified in the screen modulate
antimitotic responses, we then used single-cell time-lapse imag-
ing to directly correlatemitotic behavior with subsequent cell fate.130 Cancer Cell 28, 129–140, July 13, 2015 ª2015 The AuthorsRESULTS
A Genome-wide Screen for Regulators of Mitotic
Cell Fate
The competing-networks model predicts that suppressing death
signals during mitotic arrest provides more time for cyclin B1
degradation, thereby shifting cell fate fromdeath to slippage (Fig-
ure 1A). To test this, we screened an siRNA library to identify
genes required for DiM. Because slippage results in cell survival,
we based the screen on a viability assay (Figure S1A). To maxi-
mize the assay’s dynamic range, we treated RKO cells, which
predominantly undergo DiM (Gascoigne and Taylor, 2008), with
a saturating concentration of taxol to ensure maximal mitotic
blockage and apoptotic response. We also synchronized the
cells to maximize cell death by 48 hr (Figure 1B). The primary
screen identified 325 hits (Figure S1B). To filter out off-target
hits, we performed a secondary screen using a pool of four
different siRNAs, yielding 100 hits. Because taxol-induced death
requires mitotic entry and robust spindle checkpoint activation,
we predicted that in addition to DiM genes, the screen would
also uncover genes required for cell cycle progression and SAC
function. Indeed, we identified all the known SAC components,
several kinetochore proteins required for SAC function and the
entire chromosomal passenger complex, plus several genes
required for mitotic entry (Figure 1C). To distinguish cell cycle
andSACgenes frompotential DiMgenes,weperformeda tertiary
screen measuring mitotic index at 24 hr (Figure 1B) and plotted it
against viability at 48 hr (Figure 1C). To hone in on potential DiM
genes, we focused on hits with a high mitotic index at 24 hr and
a substantial viability score at 48 hr (Figure 1C). Time-lapse mi-
croscopy showed that siRNA pools targeting KCNK1, ZNF791,
SNTA1, and MYC shifted cell fate from death to slippage (Fig-
ureS1C). Importantly,mitotic exit wasnot accelerated, indicating
inhibition of apoptosis rather than SAC override.
Myc Is a Regulator of Cell Fate following Prolonged
Mitotic Arrest
Of the four hits, we first focused on MYC, which encodes the
bHLH-Zip transcription factor c-Myc (hereafter Myc). Myc, a
potent oncogenederegulated inmany cancers, regulates amulti-
tude of genes via both transcriptional amplification and co-fac-
tor-dependent activation/repression (Conacci-Sorrell et al.,
2014; Eilers and Eisenman, 2008; Hann, 2014; Wolf et al.,
2015). Myc thus drives numerous biological pathways including
proliferation, biogenesis, and metabolism which, when deregu-
lated, promote transformation and tumorigenesis. Because
Myc can also drive apoptosis, primarily via the ARF-MDM2-p53
pathway (Lowe et al., 2004; McMahon, 2014), we considered it
an attractive candidate for a DiM gene. To validate Myc as a
bona fide on-target hit, we deconvolved the siRNA pools, identi-
fying four distinct siRNAs that repressed Myc and inhibited DiM
(Figures S1D and S2A). When combined, these four siRNAs
reduced Myc protein levels by 90% and shifted cell fate in favor
of slippage (Figures 2A and 2B). In nine control experiments,
quantitating 100 cells per population, 82% of cells underwent
DiM,while 18%slipped (Figure 2C). In fiveMycRNAi populations,
45% of cells died, while 55% slipped. Moreover, titrating the
siRNAs revealed a correlation between Myc protein levels and
cell fate (Figure 2D). In addition, anRNAi-resistantMyc transgene
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Figure 2. Myc Is a Regulator of Mitotic Cell
Fate
(A) Immunoblots showing Myc inhibition.
(B) Fate profiles of RKO cells exposed to 0.1 mM
taxol following Myc RNAi.
(C) Cell fate in nine control and five Myc RNAi
populations.
(D) Correlation between Myc protein levels and cell
fate.
(E) Fate profiles of RKO cells exposed to 0.1 mM
taxol and 0.5 mM JQ1.
(F) Time spent arrested in mitosis; entire population
(gray), cells that die (red), and cells that slip (blue).
(G) Time arrested in mitosis with lines con-
necting cells from the same population. **p < 0.01,
****p < 0.0001.
See also Figure S2.reverted the fate profile back toward DiM (Figure S2B). To further
validate Myc, we turned to non-RNAi modalities, in particular the
small molecules DMSO and JQ1 (Figure S2C). DMSO, which
blocks transcriptional elongation of MYC (Eick and Bornkamm,
1986), efficiently suppressed Myc in RKO cells (Figure S2C) and
reduced DiM from 92% to 58% (Figure S2D). JQ1 displaces the
Brd4 transcriptional elongation factor from the MYC promoterCancer Cell 28, 129(Filippakopoulos et al., 2010; McKeown
and Bradner, 2014) and accordingly JQ1
inhibited Myc expression in RKO cells (Fig-
ure S2C). This was accompanied by a sub-
stantial effect on proliferation (Figure 2E).
However, of the cells that did enter mitosis,
only 56% were killed by taxol, demon-
strating a shift in favor of slippage (Fig-
ure 2E). Significantly, a Myc cDNA resisted
the DMSO and JQ1 effects and restored
DiM (Figure S2D). To determine whether
Myc’s role in DiM depends on its ability to
modulate gene expression, we turned to
Omomyc, a mutant bHLH-Zip domain
that sequesters Myc in complexes unable
to bind to E-boxes (Soucek et al., 2002).
Inducing Omomyc in RKO cells inhibited
DiM (Figure S2B), indicating that Myc
most likely promotes DiM via its canonical
role as a transcription factor. Interestingly
Myc V394D, which cannot bind the
Miz1 transcriptional repressor (Wiese
et al., 2013), rescued Myc RNAi (Fig-
ure S2B), suggesting that Myc promotes
DiM largely via transcriptional activation.
Taking together the RNAi data, the DMSO,
JQ1, and Omomyc experiments, we
conclude that Myc is a key determinant of
cell fate following prolonged mitotic arrest.
Using Myc to Test the Competing-
Networks Model
The competing-networks model predicts
that suppressing mitotic death providesmore time for cyclin B1 degradation, thus shifting the balance
toward slippage. A corollary is that the average time spent in
mitosis should increase (Figure 1A). Consistently, whereas
controls spent 17.1 hr arrested in mitosis, Myc-deficient cells
spent 21.3 hr (Figure 2F) arrested in mitosis. Moreover, when
we compared the cells that died, controls took 16.0 hr, whereas
Myc-deficient cells took 20.4 hr; thus, even if a cell did not–140, July 13, 2015 ª2015 The Authors 131
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Figure 3. A Cluster of Redundant BH3-Only
Proteins Promote Death in Mitosis
(A) Gene expression changes following Myc RNAi;
y axis shows the fold change and circle sizes
reflect the number of transcripts detected. Hori-
zontal lines represent mean ± 1 SD.
(B–E) Fate profiles of RKO cells exposed to 0.1 mM
taxol following tet-induced overexpression of
Bcl-xL (B); RNAi-mediated co-repression of Myc
and Bcl-xL (C); RNAi-mediated co-repression of
Bim, Bid, and Noxa (D); and tet-induced over-
expression of Bim following Myc RNAi (E).
See also Figure S3 and Table S3.escape death, inhibiting Myc delayed its onset. Slippage typi-
cally took longer than DiM (Figure 2G) and the time from mitotic
entry to slippagewas not significantly affected byMycRNAi (Fig-
ure 2F), consistent with the notion that the two competing net-
works are independent, and that Myc influences the death
pathway but not the slippage pathway.
Myc Inhibition Deregulates an Apoptosis Module
To define how Myc promotes DiM, we interrogated mitosis and
apoptosis gene expression modules using Nanostring technol-
ogy. With the exception of Cenp-T, all the mitosis genes were
suppressed following Myc RNAi (Figure 3A), reflecting Myc’s
role as a transcriptional amplifier and/or cell cycle driver. Of
the three notably repressed genes, Survivin and Mad2 promote
chromosome alignment and SAC function. Consistently, in the
absence of taxol, whereas overall mitotic timing was normal in
Myc RNAi cells, chromosome alignment was delayed slightly
and anaphase onset slightly accelerated (Figure S3A). Neverthe-
less, despite these subtle effects on an unperturbedmitosis, Fig-
ure 2 clearly demonstrates that Myc-deficient cells mount a
robust SAC response in 100 nM taxol, suggesting that mitotic
deregulation is unlikely to account for the shift in cell fate. We
therefore turned to the apoptosis module, which included 12 up-
regulated and six downregulated genes (Figure 3A). Because132 Cancer Cell 28, 129–140, July 13, 2015 ª2015 The AuthorsMyc RNAi promotes survival, the domi-
nant effectors are likely to be upregulated
pro-survival genes and/or downregulated
pro-death genes. Of the upregulated
genes, Bcl-xL is a well-established pro-
survival factor, while three of the down-
regulated genes, namely Bid, Bim, and
Noxa, encode BH3-only pro-apoptotic
proteins (Figure 3A). Because these are
Myc effectors in other contexts (McMa-
hon, 2014), we analyzed them in more
detail.
BH3-Only Pro-apoptotic Proteins
Are Redundant Effectors of Myc
Consistent with Myc’s known ability to
repress Bcl-xL (Eischen et al., 2001),
Myc RNAi elevated Bcl-xL protein levels
in RKO cells (Figure S3B). Ectopic over-
expression of Bcl-xL suppressed both
DiM and post-mitotic apoptosis (Figures3B and S3C), supporting the notion that Bcl-xL is a potent mitotic
survival factor (Bah et al., 2014; Minn et al., 1996; Upreti et al.,
2008). However, ectopic Bcl-xL enhanced survival more potently
than Myc RNAi, suggesting that other consequences of Myc
inhibition attenuate the pro-survival effect of increased Bcl-xL
(Eichhorn et al., 2014). Indeed, whereas Mcl1 transcripts fell
only marginally upon Myc RNAi, Mcl1 protein levels fell substan-
tially (Figures S3B and S3E), possibly due to deregulation of
factors involved in Mcl1 turnover. However, in taxol-arrested
cells, this residual Mcl1 appeared to resist mitotic degradation
(Figure S3E). Nevertheless, despite these complexities, we
reasoned that Bcl-xL upregulation alone is unlikely to explain
the Myc RNAi phenotype, and therefore we turned our attention
to the downregulated pro-death genes.
The downregulated BH3-only proteins (Figure 3A), namely
Bid, Bim, and Noxa, are known to be upregulated by Myc,
either directly or via the ARF-MDM2-p53 pathway (McMahon,
2014). If Bid, Bim, and Noxa are important Myc DiM effectors,
then their inhibition should mimic Myc RNAi. However, because
they did not manifest in the screen they are unlikely to be
essential for DiM. Indeed, repression of each in isolation or in
pairs had little effect on mitotic fate (Figure S3G). In contrast,
co-repression of Bim, Bid, and Noxa tipped the balance in favor
of slippage (Figure 3D), consistent with them being redundant
A B
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Figure 4. Myc Promotes Post-mitotic Death
(A) Apoptosis induction in cell lines indicated
exposed to various antimitotic agents following
Myc RNAi.
(B) Graph quantitating death following slippage in
the presence of 0.1 mM taxol.
(C) Fate profiles of wild-type and p53-deficient
HCT116 cells following Myc RNAi then exposed to
the Mps1 inhibitor AZ3146 (2 mM). Numbers indi-
cate percentage of cells that undergo one division
(white), multiple divisions (black), post-mitotic
death (green), and DiM (red).
(D) Fate profiles of RKO cells exposed to 10 nM
taxol in combination with 100 nMWEHI-539. In (C),
0 hr is when imaging started.*p < 0.05, **p < 0.01.
See also Figure S4 and Table S4.downstream effectors of Myc. A corollary is that overexpres-
sion of any one should revert the Myc RNAi phenotype. Indeed,
transgenic Bim restored DiM in Myc RNAi cells (Figures 3E and
S3H). Consistent with the competing-networks concept, Bim/
Bid/Noxa RNAi extended mitotic timing, whereas induction of
Bim accelerated the onset of DiM (Figure S3I). We conclude
therefore that Bim, Bid, and Noxa are redundant Myc effectors
required for DiM.
MYC Sensitizes Various Cancer Lines to
Antimitotic Drugs
To test the role of Myc in a wider context, we inhibited Myc in 12
cell lines derived from colon, lung, breast, cervical, and ovarian
cancers (Figure S4A), then exposed them to a panel of antimi-
totic drugs including agents targeting Eg5/KSP, Plk1, Cenp-E,
Aurora A, Aurora B, and Mps1. To monitor apoptosis, we used
time-lapse imaging to measure caspase-3/7 activity. The effects
of inhibiting Myc were strikingly consistent, significantly attenu-
ating apoptosis in nine lines (Figure 4A). Interestingly, Myc inhibi-
tion had little effect in three lines, namely DLD-1, H1703, and
Caov-3. The competing-networks model may explain these ex-Cancer Cell 28, 129–ceptions. DLD-1 cells slip very quickly
(Gascoigne and Taylor, 2008); therefore,
despite inhibiting DiM, slippage would
be expected to continue such that Myc
RNAi has little effect. Conversely, H1703
cells die very quickly and rarely slip,
suggesting that despite delaying DiM,
slippage may not be fast enough to
permit exit. Nevertheless, Myc promotes
apoptosis in a variety of cancer lines
exposed to various antimitotic agents.
MYC Promotes Apoptosis following
Slippage
In contrast to taxol, drugs targeting
Aurora B and Mps1 drive cells through
an aberrant mitosis (Keen and Taylor,
2009), suggesting that Myc also pro-
motes apoptosis following slippage.
Indeed, following exit from a prolonged
taxol arrest, Myc RNAi reduced celldeath from 60% to 25% (Figure 4B). Moreover, in response
to an Mps1 inhibitor, Myc RNAi reduced post-mitotic
apoptosis from 40% to 18% (Figure 4C) and enhanced colony
formation (Figure S4B). Canonical Myc-driven apoptosis in-
volves the ARF-MDM2-p53 pathway; however, because p53
is disengaged during mitosis, Myc-dependent DiM is likely
p53-independent. Indeed, Myc RNAi suppressed apoptosis
in p53-deficient HCT116 cells treated with mitotic blockers
(Figure 4A). Consistent with p53 restraining further cell cycle
progression following an aberrant mitosis (Thompson and
Compton, 2010), p53 deletion increased the number of
HCT116 cells entering a second mitosis from 32% to 68% (Fig-
ure 4C). However, apoptosis was only slightly affected by p53
loss, 30% versus 40% in controls, indicating that post-mitotic
apoptosis is largely p53-independent. Interestingly, whereas
Myc RNAi only had a marginal effect on post-mitotic apoptosis
in p53-deficient cells, it increased the number of p53-proficient
cells entering a second mitosis from 32% to 58% (Figure 4C).
Thus, following an aberrant mitosis, Myc not only enhances
post-mitotic apoptosis but also suppresses cell cycle progres-
sion, possibly via the ARF-MDM2-p53 pathway.140, July 13, 2015 ª2015 The Authors 133
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Figure 5. Overexpression of Myc Sensitizes
Cancer Cells to Antimitotic Agents
(A) Fate profiles and box-and-whisker plot showing
time to DiM in RKO cells exposed to 0.1 mM taxol
following tet-induced overexpression of Myc.
(B) Gene IC50 effects forMYC comparing antimitotic
agents with other drugs.
(C) Heatmaps showing gene expression profiles
of 22 breast tumors (six non-responders and 16
complete/near-complete responders) treated with
capecitabine and docetaxel.
(D) Box-and-whisker plots showing Myc and Bcl-xL
expression levels in non-responsive (N) and
responsive tumors (C).
(E) Bar graphs showing correlations between
MYC and the SAC, cell cycle, and apoptosis genes.
*p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S5 and Tables S5 and S6.Myc Enhances Survival in Low-Dose Taxol
In breast cancers, taxol does not accumulate to concentrations
high enough to induce prolonged mitotic arrest; rather cells
progress through mitosis, albeit with chromosome segregation
errors (Zasadil et al., 2014). Because Myc promotes post-mitotic
death, we reasoned that Myc would also influence low-dose
taxol responses. To test this, we reduced the taxol concentration
to 10 nM (Figure S4C), a concentration in cell culture medium
that results in intracellular concentrations similar to those
measured in breast cancer (Zasadil et al., 2014). In 10 nM taxol,
most RKO cells died in mitosis but 31% divided, indicating that
the taxol concentration was ‘‘on the edge’’ (Figure 4D). Of those
that divided, 12.5% died in the next interphase. Strikingly, Myc
RNAi cells spent considerably less time in mitosis then divided,
indicating that the SAC became satisfied (Figure 4D). Consis-
tently, Myc RNAi slightly accelerated anaphase onset during
an unperturbed mitosis (Figure S3A). Following division in
10 nM taxol, Myc RNAi cells survived, at least for the duration
of the experiment. These divisions are unlikely to be normal;134 Cancer Cell 28, 129–140, July 13, 2015 ª2015 The Authorsindeed, when we added 100 nM WEHI-
539, a selective Bcl-xL inhibitor (Lessene
et al., 2013), all the cells that divided
subsequently died (Figures 4D and S4C).
Thus, inhibiting Myc enhances survival in
low-dose taxol but this can be ameliorated
by inhibition of Bcl-xL.
Tumor Cells Overexpressing MYC
Are Sensitive to Antimitotic Agents
Because inhibiting Myc suppresses
apoptosis in response to antimitotic
agents, we asked whether elevating Myc
expression had the opposite effect.
Indeed, tet-induction of a Myc transgene
in RKO cells accelerated DiM by 2.3 hr
and reduced slippage, albeit modestly
(Figure 5A). Moreover, of the cells that
slipped, overexpressing Myc increased
post-mitotic death from 46% to 78%.
Consistently, overexpressing Myc inRat1a cells enhances colcemid-induced apoptosis (Li and
Dang, 1999). To examineMyc overexpression in a wider context,
we interrogated the Genomics of Drug Sensitivity in Cancer
database (Garnett et al., 2012), which describes 665 cell lines,
47 of which overexpress Myc, in response to 141 drugs, 11 of
which target microtubules or mitotic regulators. The mean half-
maximal inhibitory concentration (IC50) effect for the 11 antimi-
totic drugs was 0.47 compared to 0.83 for the other 130 drugs
(Figures 5B and S5A), confirming that tumor cells overexpressing
Myc are more sensitive to antimitotic agents compared to drugs
in general.
To determine whether the Myc overexpression effect
extended to patient chemotherapy responses, we interrogated
microarray datasets from XeNA, a clinical trial examining
response rates in women with operable, early stage breast
cancer receiving neoadjuvant capecitabine plus the antimitotic
agent docetaxel (Glu¨ck et al., 2012). Tumors from patients
showing complete or near-complete responses tended to have
elevated Myc (Figures 5C and 5D). Next, we analyzed the SAC
Figure 6. MYC-Deficient Crypts Are Resistant to Taxol-Induced
Apoptosis
Immunohistochemical staining and quantitation of cleaved caspase 3 in
intestinal sections fromwild-type andMYCmutant mice following 3, 6, and 9 hr
exposure to taxol. Bar represents 50 mm. *p < 0.05.and cell cycle genes identified by the siRNA screen (Figure 1C),
and the Myc regulated genes identified by our Nanostring
analysis (Figure 3A). Although there was no obvious overall cor-
relation between Myc and several housekeeping genes, Myc
correlated positively with the SAC, cell cycle, and apoptosis
genes (Figures 5C and 5E). Moreover, the SAC, cell cycle, and
Myc clusters were elevated in the responsive tumors (Fig-
ure S5B). The elevation was not simply due to a global increase
in gene expression because Bcl-xL displayed a negative correla-
tion (Figures 5C–5E), consistent with Myc-induced suppression
(Figure 3A). Moreover, the correlation between Myc and cell cy-
cle/SAC genes was not simply due to increased proliferation,
because Her2-positive tumors did not show a similar pattern
(Figures 5E and S5C). These results suggest that a positive
response to antimitotic chemotherapy requires entry into
mitosis, a robust SAC response, and the ability to undergo
Myc-dependent apoptosis.
Myc Is Required for Taxol-Induced Apoptosis in Mouse
Intestinal Crypts
The correlation between Myc expression and chemotherapy re-
sponses is provocative. However, Her2-negative breast cancers
include various tumor subtypes and XeNA used multiple chemo-
therapy agents. We therefore turned to a genetically constrained
model system that allows single agent exposure to validate the
role of Myc in the context of an intact tissue. Mice harboring a
conditional MYC allele provided such a system (Phesse et al.,
2014). AhCre+ MYCfl/fl mice were injected with b-napthoflavone
to delete MYC in the small intestine. Four days later, taxol was
administered to induce mitotic arrest and then apoptosis was
measured with caspase 3 staining (Radulescu et al., 2010). In
Myc-deficient intestines, we observed 0.2 apoptotic cells per
intestinal crypt compared to 1.2 in Myc-proficient controls (Fig-
ure 6). We conclude therefore that Myc is a determinant of
mitotic cell fate in the mouse intestine.
Interrogating Kcnk1, Snta1, and Znf791
The transcript profiling and functional experiments indicate that
Myc enhances DiM by suppressing Bcl-xL and upregulating
BH3-only proteins (Figure 3). However, a defining feature of
Myc is its ability to modulate numerous genes thereby influ-
encing various biological processes, including biosynthesisand metabolism pathways (Conacci-Sorrell et al., 2014; Eilers
and Eisenman, 2008). Consequently, Myc targets not included
in the Nanostring analysis could contribute to the phenotype.
Moreover, the screen identified KCNK1, ZNF791 and SNTA1
(Figure S1C), but it is not immediately obvious how they might
modulate apoptosis. To address these issues, we deconvolved
the Kcnk1, Znf791, and Snta1 siRNA pools. In each case, only
a single siRNA sequence enhanced viability, suggesting that
they were ‘‘off-target’’ hits (Figure S1D). When transfected in
isolation, the active Znf791 and Snta1 siRNAs accelerated
mitotic exit rather than delaying DiM (Figure S1E). In contrast,
the active Kcnk1 siRNA induced a Myc-like phenotype, sup-
pressing DiM without accelerating mitotic exit. Therefore, to
identify the target of this siRNA, and to interrogate Myc target
genes not included in the Nanostring analysis, we turned to
global gene expression profiling.
Egr1 Promotes Death in Mitosis
RKO cells were transfected with Myc, Kcnk1, and Snta1 siRNAs
and then cDNA libraries were sequenced using Illumina HiSeq
technology. Myc RNAi induced numerous changes, with 955
downregulated genes and 1,214 upregulated genes (Figure 7A).
The effect onMyc itself was relatively modest, possibly reflecting
negative auto-regulation (Conacci-Sorrell et al., 2014). Gene
ontology analysis highlighted ribosome biogenesis, metabolism,
gene expression, cell cycle, and apoptosis pathways (Fig-
ure S6C), consistent with known Myc functions. The Kcnk1
siRNA affected 424 genes, with KCNK1 itself one of the most
repressed (Figure 7A). Whereas gene ontology analysis also
highlightedmetabolism and biosynthesis pathways, the p values
and fold enrichment scores were substantially lower (Fig-
ure S6C), indicating that DiM can be suppressed without major
effects on metabolism and biosynthesis pathways.
To understand how the active Kcnk1 siRNA suppresses DiM,
we focused on the 58 downregulated genes in commonwithMyc
(Figure 7B). Only two were repressed more than 2-fold in both
conditions, namely SNORD102 and EGR1. Of these, Egr1, a
zinc finger transcription factor, stands out as it is an established
Myc target required for Myc-dependent, p53-independent
apoptosis, and it cooperates with Myc to upregulate Bim and
Noxa (Boone et al., 2011; Wirth et al., 2014). We reasoned there-
fore that the Kcnk1 siRNA might suppress DiM via inhibition of
Egr1. Consistently, transcript profiling indicated that Bim, Bid,
and Noxa were reduced following Kcnk1 siRNA (not shown).
To test directly whether Egr1 promotes DiM, we transfected
RKO cells with siRNAs specifically targeting Egr1. Strikingly,
this shifted cell fate from DiM to slippage in a manner compara-
ble to Myc siRNA (Figure 7C). Thus, these observations identify
EGR1 as a ‘‘DiM’’ gene and suggest that KCNK1 manifested in
the screen because of off-target activity toward Egr1.
Myc Modulates DNA Damage Accumulation in Mitosis
AlthoughMycandEgr1appear to set the stage forDiM,what actu-
ally triggers apoptosis during a prolongedmitotic arrest is unclear.
During the course of this work, we made two observations sug-
gesting that Myc may modulate two recently identified mecha-
nisms (Hayashi et al., 2012; Orth et al., 2012). First, we noted
that ICAD, the inhibitor of CAD, was markedly reduced by Myc
RNAi (Figure 3A). This was intriguing in light of the demonstrationCancer Cell 28, 129–140, July 13, 2015 ª2015 The Authors 135
AB
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Figure 7. Egr1 Is a Regulator of Mitotic Cell
Fate
(A) Volcano plots showing gene expression changes
following Myc and Kcnk1 RNAi.
(B) Venn diagram and scatterplot showing common
downregulated genes.
(C) Fate profiles of RKO cells exposed to 0.1 mM taxol
following Egr1 RNAi and immunoblots showing
reduced Egr1 following Myc RNAi.
See also Figure S6 and Table S7.that CAD-dependent DNA damage incurred during mitosis acti-
vatesp53 following slippage (Orth et al., 2012). In addition tobeing
an inhibitor of CAD, ICAD is also a chaperone essential for CAD
function (Nagase et al., 2003), and accordingly, inhibition of both
ICAD and Myc reduced CAD (Figure S7A). Moreover, ICAD RNAi
suppressed DiM (Figure 8A), suggesting that by stabilizing CAD,
Myc promotes accumulation of DNA damage during mitosis
thereby accelerating DiM. Consistently, g-H2AX accumulation
was less prevalent in taxol-treated Myc RNAi cells (Figure S7B).
We were also intrigued by the very rapid DiM in cells lacking
Bcl-xL and Mcl1 (Figure S3F). In addition, we noticed that in
the absence of taxol, Bcl-xL/Mcl1-deficient cells often died
upon mitotic entry (Figure S7C). However, it seems unlikely
that ICAD/CAD-dependent damage accumulates fast enough
to trigger apoptosis during an unperturbed mitosis. Indeed,
ICAD RNAi had little protective effect in cells co-depleted for136 Cancer Cell 28, 129–140, July 13, 2015 ª2015 The AuthorsBcl-xL and Mcl1 (not shown). In contrast,
telomere deprotection might cause a burst
of DNA damage upon mitotic entry (Hayashi
et al., 2012). Indeed, inhibiting Aurora B in
Bcl-xL/Mcl1-deficient cells reduced DiM
from 69% to 34% (Figure S7C) and sup-
pressing telomere deprotection by overex-
pressing TRF2 also had a protective effect
(Figures 8B and S7D). Inhibiting Myc in
Bcl-xL/Mcl1-deficient cells had an even
more penetrant effect, reducing DiM in the
absence of taxol from 69% to 10% (Fig-
ure S7C). Although this could simply reflect
Myc’s role setting the balance between pro-
survival and pro-death factors, these obser-
vations raise the possibility that Myc may
also modulate the DNA damage-inducing
pathways that trigger apoptosis during a
prolonged mitotic arrest.
DISCUSSION
The success of the siRNA screen was pred-
icated on the existence of genes essential
for DiM. Consistent with the SAC being
indirectly required for DiM (Taylor and
McKeon, 1997), we identified all the known
SAC components. Indeed, SAC genes
frequently manifest in antimitotic RNAi
screens, yet apoptotic regulators rarely do
(Dı´az-Martı´nez et al., 2014). This suggeststhat the two networks governing mitotic fate are rather different:
while the SAC consists of essential genes, the DiM network
involves redundant sub-networks. Myc drives expression of
the apoptotic network required for DiM, providing a simple
explanation for why it manifested in the screen. The different ar-
chitectures of the two networks may reflect evolutionary origins
and/or buffering capacities. The SAC, which is conserved from
yeast to man, is an ‘‘all-or-nothing’’ mechanism that responds
to a single input, unattached kinetochores, and is not buffered
by transcription (Lara-Gonzalez et al., 2012). In contrast,
apoptosis, a metazoan characteristic, responds to multiple in-
puts and can be ‘‘fine-tuned’’ by transcriptional buffering de-
pending on developmental context and homeostatic pressures
(Barkett and Gilmore, 1999). The differing architectures also
support the notion that they are largely independent (Gascoigne
and Taylor, 2008; Huang et al., 2010).
A B
C
Figure 8. Inhibition of ICAD Enhances Slippage
(A) Fate profiles of RKO cells exposed to 0.1 mM taxol following ICAD RNAi.
(B) Fate profiles of RKO cells in the absence of taxol following RNAi-mediated
co-repression Bcl-xL/Mcl1 plus tet-induced overexpression of TRF2. In (B),
0 hr represents when imaging started.
(C) Mechanistic model, see text for details.
See also Figure S7.In addition to driving proliferation, Myc overexpression drives
apoptosis via ARF-MDM2-p53 (McMahon, 2014). Because p53
is disengaged during mitosis, it is not clear how this mechanism
could contribute to DiM, and indeed p53 is not required for Myc-
dependent mitotic death. Moreover, Myc can upregulate Bim,
Bid, and Noxa independently of p53 (Campone et al., 2011;
Egle et al., 2004; Eischen et al., 2001; Hemann et al., 2005; Iac-
carino et al., 2003; Muthalagu et al., 2014; Nikiforov et al., 2007).
Recent evidence shows that Myc drives p53-independent
apoptosis by cooperating with Egr1, itself a Myc target (Boone
et al., 2011). Myc promotes EGR1 expression via a non-canoni-
cal mechanism involving ARF and in turn, Myc and Egr1 are co-
recruited to the promoters of BIM andNOXA (Boone et al., 2011;
Wirth et al., 2014). It seems likely, therefore, that in interphase,
Myc and Egr1 upregulate a cluster of redundant pro-apoptotic
BH3-only proteins and suppress Bcl-xL, establishing the
apoptotic network which can later induce DiM without the
need for p53 engagement and de novo gene expression. Uponentry into mitosis, the apoptotic network is balanced so that a
pro-survival environment is maintained (Figure 8C). However,
in the presence of mitotic blockers, the balance slowly tips in
favor of the pro-apoptotic BH3-only proteins, eventually trig-
gering cell death. Several processes help tip the balance,
including accumulation of DNA damage due to partial CAD acti-
vation and telomere deprotection (Hayashi et al., 2012; Orth
et al., 2012). Also, slow degradation of Mcl1, possibly due to
incomplete APC/C inhibition (Harley et al., 2010), weakens pro-
survival function. When Myc is inhibited, the initial balance is
more heavily weighted toward pro-survival, mitotic death is
thus delayed providing more time for CyclinB1 degradation
and slippage. Myc inhibition may also suppress DNA damage
accumulation, weakening the apoptotic trigger. When Bcl-xL
and Mcl1 are co-inhibited, the balance is so heavily weighted to-
ward pro-death that cells cannot survive a short mitotic arrest,
and even an unperturbed mitosis can induce apoptosis.
Myc is also required for efficient apoptosis in response to
drugs that drive cells through an aberrant mitosis. Whether this
is because these cells inherit an apoptotic balance tipped in
favor of pro-survival or cannot initiate a robust post-mitotic
response remains to be seen. Consistent with the latter, Myc
also promotes cell cycle restraint following SAC override. One
possibility to account for this is the ARF-MDM2-p53 pathway;
by inducing ARF and thus suppressing MDM2, Myc may sensi-
tize the p53-dependent mechanism that detects DNA damage
incurred when chromosomes missegregate (Janssen et al.,
2011). This may explain why ARF-deficient mouse embryonic
fibroblasts tolerate aneuploidies (Silk et al., 2013). Alternatively,
following chromosome missegregation induced by SAC over-
ride, Myc’s ability to drive global gene expression might elevate
the proteotoxic burden that arises in aneuploid daughter cells,
thus enhancing cell cycle suppression (Tang and Amon, 2013).
Interestingly, several mitotic regulators are synthetic lethal with
Myc overexpression, including Cdk1, Survivin, Aurora B, and
the SUMO-activating enzyme SAE-2 (den Hollander et al.,
2010; Goga et al., 2007; Kessler et al., 2012; Yang et al., 2010).
Whether this is due to deregulation of mitosis per se as opposed
to deregulation of cellular responses to mitotic abnormalities is
unclear. Consistent with the former, SAE-2 modulates a spindle
assembly gene expression program (Kessler et al., 2012).
Consistent with the latter, our observations show that Myc en-
hances both DiM and post-mitotic responses.
Antimitotic agents continue to be important frontline drugs,
emphasized by the impressive effect of combining taxanes
with targeted therapies in the treatment of breast cancer (Slamon
et al., 2001). Whether taxanes inhibit tumor growth via antimitotic
or other tubulin-dependent mechanisms remains unclear (Kom-
lodi-Pasztor et al., 2012; Mitchison, 2012). Consistent with Myc
enhancing antimitotic apoptosis, ovarian cancers treated with
taxol and carboplatin responded better if Myc was more highly
expressed (Iba et al., 2004). Consistently, Her2-negative breast
cancers that responded to docetaxel and capecitabine had
higher Myc levels. The correlation between Myc and cell cycle/
SAC genes is especially striking because Her2-positive tumors
do not show a similar pattern. This suggests that docetaxel-ca-
pecitabine responses require cell cycle progression and a robust
SAC response. In contrast, anti-tumor effects mediated by tras-
tuzumab-docetaxel-capecitabine are more likely dominated byCancer Cell 28, 129–140, July 13, 2015 ª2015 The Authors 137
inhibition of Her2-dependent PI3K/Akt survival signaling (Berns
et al., 2007), and therefore less dependent on mitotic entry and
SAC activation. Taken together, these observations suggest
that the Myc network may yield potential biomarkers. However,
a recent study found that while triple-negative breast cancers ex-
hibited elevated Myc expression, this did not predict responses
to neoadjuvant chemotherapy (Horiuchi et al., 2012). Consistent
with the mechanisms we describe here, this study did however
observe that elevated Myc sensitized triple-negative cells to
Cdk1 inhibition in a Bim-dependent, p53-independent manner.
Thus, taking together our observations, the synthetic lethality re-
lationships described above, and the provocative clinical obser-
vations, there is considerable merit in further exploring the links
between the BH3-only/Bcl-xL pathway and mitotic regulators in
the context of Myc-driven tumors. Interestingly, Myc inhibition
had little effect on three cell lines we studied, suggesting that
this avenue may provide insight into intrinsic resistance, while
changes and/or heterogeneity in Myc expression may provide
insight into acquired taxane resistance.
Myc suppresses Bcl-xL in various contexts (Eischen et al.,
2001) and they inversely correlate in the breast cancer gene
expression profiles we analyzed. Moreover, Bcl-xL overexpres-
sion potently blocks Myc-driven apoptosis (Pelengaris et al.,
2002) and our observations reaffirm Bcl-xL as a potent mitotic
survival factor. Although Mcl1 and Bcl-xL can partially compen-
sate for each other during mitosis (Shi et al., 2011), degradation
of Mcl1 during a mitotic arrest means that Bcl-xL becomes
particularly critical following slippage. Because slippage is a clin-
ically relevant phenotype (Zasadil et al., 2014), these observa-
tions make a compelling case for combining Bcl-xL inhibitors
with antimitotic agents. Indeed, the Bcl2/Bcl-xL inhibitor navito-
clax sensitizes ovarian cancer cell lines to taxol (Wong et al.,
2012). Similar combination strategies may also help revive the
prospects of targeted antimitotic agents that have thus far
been disappointing in the clinic (Komlodi-Pasztor et al., 2012;
Mitchison, 2012). ExploringMyc-dependent apoptotic pathways
for predicative biomarkers may also facilitate better clinical eval-
uation of these agents. Finally, as a potent driver of tumorigen-
esis, Myc is itself an attractive anti-cancer target (McKeown
and Bradner, 2014; Sodir and Evan, 2011). However, if superim-
posed on existing taxane chemotherapy regimens, targeting
Myc may be counterproductive, weakening both the SAC and
post-mitotic apoptosis, thereby fueling genomic instability.
This should not detract fromMyc as a target as long asmitigating
strategies are also explored. Our observation that pharmacolog-
ical inhibition of Bcl-xL potently restores apoptosis in Myc-defi-
cient cells exposed to low-dose taxol further supports the case
for exploring Bcl-xL inhibitors in the context of antimitotic
agents.EXPERIMENTAL PROCEDURES
siRNA Library Screen
RKO cells were synchronized for 16 hr using 2 mM thymidine, released then
seeded in 96-well plates (Greiner Bio-One) containing Opti-MEM media (Life-
Technologies), DharmaFECT 1 transfection reagent (Dharmacon), and siRNAs
at a final concentration of 66 nM, after which 0.1 mM taxol and viability reagent
(CellTiter 96 AQueousOne Solution Cell Proliferation Assay, Promega) were
added after 24 and 68 hr, respectively, and the absorbance at 490 nm
measured after 72 hr. For the tertiary screen, the mitotic index at 24 hr was138 Cancer Cell 28, 129–140, July 13, 2015 ª2015 The Authorsdetermined using a BD Pathway (BD Biosciences). Cell lines and small mole-
cule inhibitors are described in the Supplemental Experimental Procedures.
Functional Experiments
siRNAs and DharmaFECT 1 combined in Opti-MEM media were added to
RKO cells plated at 10 3 104 cells/ml, yielding a final siRNA concentration
of 66 nM. For siRNA sequences, see the Supplemental Experimental Proce-
dures. Open reading frames described in the Supplemental Experimental Pro-
cedures were cloned into pcDNA5/FRT/TO based vectors and isogenic, tetra-
cycline-inducible, stable cell lines generated by co-transfection with pOG44
(Invitrogen) into Flp-In T-REx RKO cells. Phase contrast imaging, cell prolifer-
ation, and apoptosis measurements were performed on an IncuCyte ZOOM
(EssenBioScience) with CellPlayer Kinetic Caspase-3/7 Apoptosis Assay Kit
(EssenBioSciences). Image sequences were analyzed manually and statisti-
cal analysis performed with GraphPad Prism. On fate profiles, 0 hr corre-
sponds to mitotic entry unless stated otherwise in the legend. Immunoblotting
was performed using antibodies described in the Supplemental Experimental
Procedures.
Gene Expression Profiling
Cells transfected with siRNAs were synchronized, released for 5 hr, then RNA
was prepared using Trizol (Life Technologies). One hundred nanograms of
RNA was hybridized with custom nCounter Reporter and Capture probe
sets (Nanostring Technologies) at 65C overnight, unhybridized probes
removed, complexes bound to the imaging surface, and images acquired us-
ing the nCounter Digital Analyzer. Transcript counts were normalized to house-
keeping genes using nSolver Analysis Software. For global gene expression
profiling, total RNA was processed using the Illumina TruSeq Stranded
mRNA Sample Preparation Kit, then cDNA libraries sequenced on an Illumina
HiSeq 2000 using single read, 50 cycle runs. Quality of sequencing reads was
assessed using FastQC (Babraham Bioinformatics) and aligned to a reference
genome (hg19, UCSC Genome Browser) using TopHat. Sequencing yielded
on average 23.7 million unique reads per sample with a 60.7%–65.7% map-
ping rate. Cufflinks was used to generate transcript abundance as fragments
per kilobase of transcript per million mapped reads (FPKM), and statistical
analysis of FPKM values was calculated using R (Bioconductor).
Inactivation of Myc in the Mouse Intestine
Cre-mediated inactivation ofMYC in the intestinal epithelium was induced via
three intraperitoneal (i.p.) injections of 80 mg/kg b-naphthoflavone in 1 day.
Four days later, 10 mg/kg taxol was administered via i.p. injection, tissue har-
vested after various time points, fixed in 4% formaldehyde, then stained for
cleaved caspase 3 (R&D systems). All animal experiments were conducted un-
der an appropriate animal project license approved by the UK home office and
in accordance with the Animal Welfare and Experimental Ethics Committee at
the University of Glasgow.
Statistical Methods
Statistical analysis was performed in GraphPad Prism 6 as follows: ANOVA
plus Bonferroni (Figures 2C and 2F); linear regression (Figure 2D); correlation
(Figures S1B and 5E); Paired t test (Figure 2G); Wilcoxon t test (Figure 4A);
Mann-Whitney (Figures 4B, 5A, 5B, 5D, 6, S3A, S3I, and S5B); Kruskal-Wallis
(Figure S1E). In figures, p values were *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. Scatterplots show mean and SD. Unless stated otherwise in
the figure legend, box-and-whisker plots show median, interquartile ranges,
plus min to max range. Figure S1D, mean ± SD; Figure S4B, mean ± SEM.
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Figure S1, related to Figure 1. A genome-wide siRNA screen for regulators of mitotic cell fate. (A) 
Workflow of the screen. (B) Result of the primary screen, plotting the robust Z scores (Z*) for the two 
replicates. Z* scores were calculated using the median absolute deviation for each plate (Chung et al., 
2008). Genes with mean Z* scores greater than 3 were taken forward to the secondary screen. (C) Fate 
profiles of RKO cells transfected with selected ON-TARGETplus SMARTpools and exposed to 0.1 µM 
taxol. (D) Bar graph showing viability of taxol-treated RKO cells after transfection of individual siRNAs 
from the SMARTpools used in the 1o and 2o screens. While siRNAs in many of the siGENOME and ON-
TARGETplus SMARTpools are distinct, in some instances there is duplication, indicated by hashtags (#) 
and paragraph symbols (¶). Myc siRNAs 4, 5, 6 and 8 repress Myc and inhibit death in mitosis (DiM) 
(Fig. S2A) so they were pooled and used for further experiments, while #4 was used in isolation for the 
RNAi-rescue experiment in Fig. S2B. Values represent mean and SD from two experiments. (E) Box-
and-whisker plots (median, interquartile and 10-90% ranges) showing that in isolation, SNTA1 #4 and 
ZNF791 #1 accelerate mitotic exit. In contrast, the active KCNK1 siRNA more closely resembles the Myc 
phenotype. 
 
 
Table S1, related to Figure 1. Primary screen; MTS values at 48 hr. Used to generate Fig. S1B. 
(Provided as an Excel file). 
 
 
Table S2, related to Figure 1. Secondary and tertiary screens; MTS values at 48 hr and mitotic index 
(granularity) values at 24 hr. Used to generate Fig. 1C. (Provided as an Excel file). 
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Figure S2, related to Figure 2. Myc is a regulator of mitotic cell fate. (A) Deconvolution of siRNA 
pools targeting Myc. Immunoblots of RKO cells transfected with four active Myc siRNAs, either as a 
pool (P) or individually (nos 4, 5, 6 and 8), and six negative controls siRNAs. Corresponding fate profiles 
of transfected RKO cells treated with 100nM taxol. (B) Analysis of Myc mutants. Immunoblots show 
induction of GFP-tagged Myc, an RNAi-resistant mutant and Omomyc in RKO cells treated with 1 µg/ml 
tetracycline. The asterisk marks a Myc-GFP cleavage product. Fate profiles as in (A). (C) Schematic 
showing how DMSO and JQ1 inhibit transcription of MYC and immunoblots confirming that DMSO and 
JQ1 inhibit Myc in RKO cells. (D) Immunoblots and fate profiles showing that a Myc-GFP cDNA is 
resistant to DMSO and JQ1 and restores the balance back towards death in mitosis.  
 4	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Figure S3, related to Figure 3. Analysis of Bcl2-family members. (A) Time lapse analysis of RKO 
cells expressing a GFP-tagged histone H2B, measuring the time from nuclear envelope breakdown 
(NEBD) to metaphase, from metaphase to anaphase and from NEBD to anaphase. Cells were either 
untreated (U), mock transfected (M), or transfected with siRNAs, either a non-targeting control (Ctrl) or 
the pool targeting Myc. Box-and-whisker plots show the median, interquartile ranges and full range. (B) 
Immunoblots showing RNAi-mediated inhibition of Myc, XIAP and pro-survival Bcl2 family proteins in 
RKO cells. Note that Myc RNAi results in up-regulation of Bcl-xL and down-regulation of Mcl1, but has 
no obvious effect on XIAP. Asterisk marks a non-specific background band. (C) Characterisation of a 
stable tet-inducible RKO cell line overexpressing Bcl-xL; immunoblot shows induction of Bcl-xL with a 
range of tetracycline concentrations. Asterisk marks the endogenous protein. Apoptosis assay shows that 
even low level induction of Bcl-xL is sufficient to block apoptosis induced by taxol. Note that 25ng/ml 
tetracycline increases Bcl-xL levels only two fold yet this is sufficient to block apoptosis. (D) 
Characterisation of a stable tet-inducible RKO cell line overexpressing XIAP; immunoblot shows 
induction of XIAP with 1 µg/ml tetracycline. Asterisk marks a non-specific background band. Fate 
profile shows that tet-induced overexpression of XIAP does not inhibit DiM in 0.1 µM taxol. (E) 
Immunoblot showing reduced Mcl1 levels in Myc RNAi cells. Consistent with Mcl1 being degraded in 
mitosis, Mcl1 is less abundant in taxol-treated cells. However, Mcl1 levels do not fall further in taxol-
treated Myc RNAi cells, possibly due to inhibition of mitotic-specific degradation. (F) Fate profiles 
following RNAi-mediated inhibition of pro-survival Bcl2 family proteins showing that co-repression of 
Bcl-xL and Mcl1 leads to rapid DiM in 0.1 µM taxol. (G) Immunoblots of RKO cells showing RNAi-
mediated inhibition of the BH3-only proteins Bim, Bid and Noxa, and fate profiles showing that while 
Myc RNAi reduces DiM in 0.1 µM taxol to 36% (compared to 69% in the corresponding control shown 
in Fig. 3D), repressing the BH3-only proteins, either in isolation (not shown) or in pairs as shown here, 
has little effect, with DiM remaining at ~70%. (H) Characterisation of an RKO tet-inducible cell line 
overexpressing Bim; immunoblot shows induction of Bim with 50 ng/ml tetracycline. The growth curves 
show that in the absence of taxol, overexpressing Bim to this level alone does not induce apoptosis. (I) 
Box-and-whisker plots (median, interquartile and 10-90 percentile range) showing the time spent arrested 
in mitosis following overexpression of Bim, either in control cells or following Myc RNAi, and following 
inhibition of Bim, Bid and Noxa. Note that overexpression of Bim accelerates death in mitosis while 
inhibition of the three BH3-only proteins delays death.   
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Table S3, related to Figure 3. Nanostring gene expression profiling data. Used to generate Fig. 3A. 
 
 
Common 
name 
Gene  
Name 
Log2 fold 
change* Reads   
Common 
name 
Gene  
Name 
Log2 fold 
change* Reads 
A
po
pt
os
is
 m
od
ul
e 
AIF AIFM1 -0.259 429 
 
M
ito
si
s m
od
ul
e 
Apc1 ANAPC1 -0.645 569 
Apaf1 APAF1 0.211 263 
 
Apc10 ANAPC10 -0.253 193 
ATM ATM 0.144 59 
 
Cenp-S APITD1 -0.602 285 
BAD BAD -0.039 69 
 
Aurora A AURKA -0.552 1217 
BAK Bak1 0.125 669 
 
Aurora B AURKB -0.513 1315 
BAX BAX -0.042 756 
 
Survivin BIRC5 -0.720 927 
Bcl2 BCL2 -0.255 34 
 
Bub1 BUB1 -0.435 1096 
Bcl-XL BCL2L1 0.477 772 
 
BubR1 BUB1B -0.581 799 
BimEL BCL2L11 -0.668 26 
 
Knl1 CASC5 -0.204 498 
BID BID -0.912 187 
 
Cyclin B1 CCNB1 -0.606 2911 
cIAP BIRC3 -0.187 60 
 
Cdc20 CDC20 -0.416 1731 
β-TrCP BTRC -0.180 194 
 
Cdc25 CDC25A -0.923 632 
Caspase 3 CASP3 0.318 359 
 
Sororin CDCA5 -0.540 895 
Caspase 7 CASP7 -0.242 261 
 
Cdh1 CDK1 -0.514 2734 
Caspase 8 CASP8 -0.167 301 
 
Cenp-E CENPE -0.332 542 
Casp8a CASP8AP2 -0.276 191 
 
Cenp-F CENPF -0.246 1208 
Caspase 9 CASP9 0.202 76 
 
Cenp-T CENPT 0.539 16 
c-FLIP CFLAR 0.059 124 
 
Separase ESPL1 -0.231 337 
CKII CSNK2B -0.289 2061 
 
Haspin GSG2 -0.441 396 
ICAD DFFA -0.753 429 
 
Augmin HAUS1 -0.447 533 
SMAC DIABLO -0.242 193 
 
Eg5 KIF11 -0.519 695 
E2F1 E2F1 -0.843 316 
 
Mad2 MAD2L1 -0.762 1663 
Fadd FADD 0.176 30 
 
p31 comet MAD2L1BP -0.291 643 
Fbw7 FBW7 -0.408 119 
 
Greatwall MASTL -0.098 238 
HRK HRK -0.543 17 
 
Mis12 MIS12 -0.560 307 
Omi HTRA2 -0.257 80 
 
Cap D2 NCAPD2 -0.414 1198 
MULE HUWE1 -0.278 767 
 
Cap G NCAPG -0.383 763 
p38 MAPK14 0.016 550 
 
Cap H NCAPH -0.630 632 
JNK1 MAPK8 -0.282 516 
 
Ndc80 NDC80 -0.331 332 
JNK2 MAPK9 -0.143 546 
 
Nde1 NDE1 -0.395 173 
Max MAX -0.608 681 
 
Plk1 PLK1 -0.579 1647 
Mcl1 MCL1 -0.312 8220 
 
Securin PTTG1 -0.153 112 
c-Myc MYC -1.085 3168 
 
Sgo1 SGOL1 -0.167 336 
Pin1 PIN1 -0.046 245 
 
Ska1 SKA1 -0.331 335 
NOXA PMAIP1 -1.080 270 
 
Smc1 SMC1A -0.519 278 
PKA PRKACA 0.149 794 
 
Smc2 SMC2 -0.477 473 
p53 TP53 -0.379 205 
 
Spindly SPDL1 -0.303 134 
Tradd TRADD 0.315 17 
 
SA2 STAG2 -0.194 730 
Usp9X USP9X -0.011 934 
 
Megator TPR -0.108 435 
XIAP XIAP 0.128 327 
 
Tpx2 TPX2 -0.460 1236 
MIZ1 ZBTB17 0.223 40 
 
Mps1 TTK -0.517 338 
      
UbcH10 UBE2C -0.429 3531 
      
Wapl WAPAL -0.381 779 
      
Zw10 ZW10 -0.199 266 
 
*Values are the mean of 4 biological replicates 
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Figure S4, related to Figure 4. Myc promotes post-mitotic death. (A) Immunoblots showing RNAi-
mediated inhibition of Myc in the panel of cell lines used in Fig. 4A. Each pair of lanes shows the non-
targeting control on the left and the Myc siRNA on the right. (B) Colony formation assay of RKO cells 6 
days following exposure to the Mps1 inhibitor AZ3146 for 96 hr. Values represent mean ± SEM from 
three independent experiments. (C) Caspase 3/7 assays showing apoptosis induction in RKO cells. Left 
panel shows a taxol titration. 10 nM was selected for the experiment in Fig. 4D. Middle panel shows that 
tet-induction of Bcl-xL blocks apoptosis in the presence of 10 nM taxol but that this is reverted by 
titrating in the Bcl-xL inhibitor WEHI-539. 100 nM was selected for the experiment in Fig. 4D. Right 
panel shows that in the absence of antimitotic agents, while 10 µM WEHI-539 induces apoptosis, 100 nM 
is relatively benign.
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Figure S5, related to Figure 5. Overexpression of Myc sensitizes cancer cells to antimitotic agents. 
(A) Volcano plot showing the gene IC50 effect and significance (inverted) of MYC-drug associations. 
Each circle represents a single drug effect and the size is proportional to the number of Myc 
overexpressing cell lines screened (range 26-50). Primary data is derived from www.cancerrxgene.org 
(Garnett et al., 2012; Yang et al., 2013). Taxol, vinorelbine, vinblastine and epothilone B are microtubule 
inhibitors; BX-795, ZM447439, and VX-680 are Aurora kinase inhibitors; GW843682X and BI-2536 are 
Plk1 inhibitors; S-Trityl-L-cysteine is an Eg5/KSP inhibitor. (B) Box-and-whisker plots (median, 
interquartile and full range) showing the relative expression levels of SAC, cell cycle and Myc-regulated 
apoptosis clusters in tumours that either do not respond (N) or show complete/near-complete responses 
(C) to capecitabine and docetaxel chemotherapy. (C) Heat maps showing gene expression profiles of 12 
Her2-positive tumours treated with capecitabine and docetaxel plus Trastuzumab (responders), indicating 
no obvious correlation with Myc. As in Fig. 5C, each column represents a patient sample and the colour 
code indicates the relative expression level of the genes indicated, with the sample with the highest value 
dark red and the lowest value dark blue. Also shown are the housekeeping controls genes to accompany 
the data in Fig. 5C. Primary data for (B) and (C) are derived from (Glück et al., 2012). 
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Figure S6, related to Figure 7. Global gene expression profiling. (A) Gene expression fold 
changes following Myc RNAi, normalized to either mock transfected (y-axis) or cells transfected 
with a non-targeting control siRNA (x-axis). Each value is the average derived from five biological 
replicates for mock and four each for the non-targeting control and Myc siRNA. Because of the 
excellent correlation, all subsequent analysis was performed with values normalized to the non-
targeting control siRNA. (B) Volcano plot showing the gene expression changes induced by 
transfection of SNTA1 siRNA #4. (C) Gene ontology analysis of the up and downregulated genes 
following transfection of siRNAs targeting Myc, Kcnk1 and Snta1. Gene Ontology analysis was 
performed with DAVID Bioinformatics Resources 6.7 (Huang da et al., 2009) then visualized with 
Revigo (Supek et al., 2011). The Snta1 siRNA deregulated 575 genes, with SNTA1 itself the most 
repressed gene. Cell cycle and mitosis-related gene ontology terms feature heavily, consistent with 
this siRNA accelerating mitotic exit. Interestingly, FoxM1, which drives G2/M gene expression was 
reduced 1.75-fold (not shown), indicating that this siRNA may disrupt mitotic controls by 
deregulating FoxM1 (Laoukili et al., 2005). (D) Venn diagram showing the number of common 
upregulated genes. (E) Fold changes for the genes analyzed in Fig. 3A showing good correlation 
between the Nanostring and RNAseq-based measurements. 
 
 
Table S7, related to Figure 7. RNA-Seq-derived gene expression analysis. Used to generate Fig. 
7A and S6B. (Provided as an Excel file). 
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Figure S7, related to Figure 8. Inhibition of ICAD/CAD and telomere deprotection enhances 
slippage. (A) Characterisation of ICAD RNAi and overexpression. Immunoblots show that 
inhibition of either Myc or ICAD reduces CAD levels. Fate profiles show that RNAi-mediated 
inhibition of ICAD in Myc RNAi cells does not further suppress DiM. Tet-induced overexpression 
of ICAD elevates levels of CAD but this has no obvious effect on DNA damage or DiM. Asterisks 
mark non-specific bands. (B) Immunoblot shows that taxol exposure induces γH2AX, indicating 
DNA damage, and that this is suppressed by Myc RNAi. (C) Fate profiles of RKO cells in the 
absence of taxol following RNAi-mediated co-repression of Bcl-xL and Mcl1. In contrast to fate 
profiles of taxol-treated cells, here, zero hr represents when imaging started as opposed to when the 
cell first entered mitosis. 69% of Bcl-xL/Mcl1-deficient cells undergo DiM, indicating that in the 
absence of pro-survival function, mitosis is a significant stress, inducing apoptosis without the 
addition of taxol. Co-repression of Myc reduces DiM in Bcl-xL/Mcl1-deficient cells to 10%, 
consistent with Myc counterbalancing pro-survival function. Exposing Bcl-xL/Mcl1-deficient cells 
to 2 µM ZM447439, a selective Aurora B inhibitor (Ditchfield et al., 2003), also reduces DiM in the 
absence taxol, to 34%. Note that Aurora B promotes telomere deprotection upon mitotic entry, 
activating a DNA damage signal (Hayashi et al., 2012). (D) Characterisation of a tet-inducible RKO 
cell line overexpressing the shelterin component TRF2, tagged with an N-terminal Myc epitope. 
Immunoblot shows induction of TRF2 with 1 µg/ml tetracycline and growth curves shows that, in 
the absence of taxol, this does not inhibit proliferation. 
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Supplemental Experimental Procedures 
 
Cell lines 
Colon carcinoma lines (RKO, DLD-1, HCT116, HT29), lung carcinoma lines (Calu6 and H1703) 
breast (MDA-MB-231) and ovarian cancer lines (SKOV3, PA1, SW626, Caov3) were obtained 
from the American Type Culture Collection. HeLa cells were as described (Taylor and McKeon, 
1997), HCT116 p53-/- were provided by Bert Vogelstein (Bunz et al., 1998). Cells were cultured in 
DMEM plus 10% fetal calf serum (LifeTechnologies), 2 mM glutamine, 100 U/ml penicillin, and 
100 U/ml streptomycin (Lonza). For PA1, SW626 and SKOV3, DMEM was replaced by Minimum 
Essential Media, Leibovitz's L-15 (Sigma-Aldrich) and McCoys (modified) 5A medium (Life 
Technologies) respectively. All lines were grown at 37oC in a humidified 5% CO2 incubator. For 
the tertiary screen, we use an RKO line expressing a GFP-tagged histone H2B (Gascoigne and 
Taylor, 2008) so that mitotic index could be approximated by measuring the granularity of the 
chromatin. 
 
siRNA sequences  
The sequences of siRNAs used in this study are listed below. All siRNAs were from Dharmacon 
unless stated otherwise. 
Target  siRNA sequence Notes 
Bcl-2  
GGGAGAACAGGGUACGAUA 
GAAGUACAUCCAUUAUAAG 
GGAGGAUUGUGGCCUUCUU 
UCGCCGAGAUGUCCAGCCA 
 
Bcl-xL  
GGACAGCAUAUCAGAGCUU 
GAAAUGACCAGACACUGAC 
CCUACAAGCUUUCCCAGAA 
UUAGUGAUGUGGAAGAGAA 
 
Bid  
GGGAUGGACUGAACGGACA 
CUAGAGACAUGGAGAAGGA 
GCACCUACGUGAGGAGCUU 
GUAACUAACUGCAUACACU 
 
Bim  UGACCGAGAAGGUAGACAA CAACCACUAUCUCAGUGCA Life Technologies 
BubR1  AACGGGCAUUUGAAUAUGAAA Positive control siRNA in library screen. (Ditchfield et al., 2003) 
Egr1  
GAUGAACGCAAGAGGCAUA 
CGACAGCAGUCCCAUUUAC 
GGACAUGACAGCAACCUUU 
GACCUGAAGGCCCUCAAUA 
 
Myc 
#4 
#5 
#6 
#8 
CGAUGUUGUUUCUGUGGAA 
AACGUUAGCUUCACCAACA 
GGAACUAUGACCUCGACUA 
CUACCAGGCUGCGCGCAAA 
These four siRNAs were pooled for 
routine use while #4 was used in 
isolation for the RNAi-rescue experiment 
(Fig. S2B). 
G1  siGLO RISC-free siRNA (D-001600-01-05) 
Additional negative control siRNA (Fig. 
S2A). 
GAPDH (GA)  UGGUUUACAUGUUCCAAUA Negative control siRNA in library screen. 
Hrk  
GGGAAGCCCUUUGGAAAUC 
GAUCGUAGAAACACAGAAU 
UCAAGGCGCUAGGCGACGA 
AGGCGGAACUUGUAGGAAC 
 
ICAD  
GGCGAGAUCCGGACUCUAA 
GACAUUCUGGCCAUUGAUA 
ACGCAGAGCUUGCAUUCUC 
GAAAGAAGAUCUGUCCAGC 
 
 19	  
KCNK1 #6 CGGUGGAGCUGCCCUAUGA Active siRNA (Fig. S1) 
Mcl1  
CGAAGGAAGUAUCGAAUUU 
GAUUAUCUCUCGGUACCUU 
GAAGGUGGCAUCAGGAAUG 
GGUUUGGCAUAUCUAAUAA 
 
Non-targeting 
(NT)   
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
Routine negative control siRNA pool. 
Noxa  
AAACUGAACUUCCGGCAGA 
GAACCUGACUGCAUCAAAA 
AAUCUGAUAUCCAAACUCU 
GCAAGAACGCUCAACCGAG 
 
Scramble (SC) AAAACCAUCAUACCAGAGACA Additional negative control siRNA (Fig. S2A). 
SNTA1 #4 CAGAUUGGCUGGCUAACUG Active siRNA (Fig. S1D) 
Tao1 (T1)  GUAAUAUGGUCCUUUCUAA Additional negative control siRNA (Fig. S2A). (Westhorpe et al., 2010) 
XIAP  
GUAGAUAGAUGGCAAUAUG 
GAACUGGGCAGGUUGUAGA 
GAAAGAGAUUAGUACUGAA 
GGACUCUACUACACAGGUA 
 
ZNF791 #1 GGGAAGACCCGAAUGUUGA Active siRNA (Fig. S1D) 
 
cDNAs 
Open reading frames were generated either by using SuperScript One-Step RT-PCR with mRNA 
prepared from HeLa or RKO cells, or PCR amplified using Pfu Turbo with a plasmid as the 
template, then cloned into a pcDNA5/FRT/TO-based vector modified to include an N-terminal Myc 
or GFP epitope tag (Girdler et al., 2006). Myc and Omomyc were engineered with a C-terminal 
GFP tag, XIAP, Bcl-xL, ICAD and TRF2 were tagged with a Myc epitope at the N-terminus, and 
Bim was untagged. All ORFs were verified by sequencing. 
Name Accession PCR primers (5’ - 3’) Source 
Bcl-xL NM_138578.1 TCTCAGAGCAACCGGGAGCTG  TCATTTCCGACTGAAGAGTGAG  RT-PCR 
Bim NM_138621.4 ATGGCAAAGCAACCTTCTG  TCAATGCATTCTCCACACC  
Thermo Scientific 
Clone ID 5213713 
Myc NM_002467.4 ATGCCCCTCAACGTTAGCTTC  CGCACAAGAGTTCCGTAG  RT-PCR 
ICAD NM_004401.2 GAGGTGACCGGGGACGCCGGG  CTATGTGGGATCCTGTCTGGC RT-PCR 
TRF2 NM_005652 GCGGGAGGAGGCGGGAGTAGC TCAGTTCATGCCAAGTC 
Addgene 16066 
(Karlseder et al., 2002) 
XIAP NM_001167.3 ACTTTTAACAGTTTTGAAGG  TTAAGACATAAAAATTTTTTGCTTG  RT-PCR 
Omomyc  
ATGGAGGAGAATGTCAAG 
CGCACAAGAGTTCCGTAG 
GTTGCGGAAACAAAACGAACAGTTGA 
TCAACTGTTCGTTTTGTTTCCGCAAC 
CAAGCAGAGACGCAAAAGCTCATTTCTGA
-AATCGACTTGTTG 
CAACAAGTCGATTTCAGAAATGAGCTTTT-
GCGTCTC 
(Soucek et al., 1998) 
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Antibodies 
Primary antibodies for immunoblotting are listed below. 
Antigen Antibody name Source/ Citation 
Bcl-xL Rabbit anti-Bcl-xL Cell Signaling Technology 
Bcl2 Mouse anti-Bcl2 BD Biosciences 
Bid Rabbit anti-Bid (Human specific) Cell Signaling 
Bim Rabbit anti-Bim BD Biosciences 
Bub3 Sheep anti-Bub3 Holland and Taylor, unpublished 
BubR1 Sheep anti-BubR1 (SBR1.1) (Taylor et al., 2001) 
Caspase 3 Mouse anti-caspase 3 Cell Signaling 
Egr1 Rabbit anti-Egr1 (588) Santa Cruz 
γH2AX Rabbit anti-γH2Ax Novus Biologicals 
pH3-Ser10 Rabbit anti-Histone H3 pSerine10 Millipore 
Myc Rabbit anti-c-Myc (Y69) AbCam 
CAD Rabbit anti-DFFB Sigma 
HRP anti-sheep/ 
mouse/ rabbit Conjugated secondaries  Invitrogen 
ICAD Rabbit anti-ICAD AbCam 
Mcl1 Rabbit anti-Mcl1 (S-19) Santa Cruz Biotechnology 
Myc epitope tag 4A6 Millipore 
Noxa Mouse anti-Noxa (114C307) Merck Millipore 
Tao1 Sheep anti-Tao1 (Westhorpe et al., 2010) 
XIAP Rabbit anti-XIAP Cell Signaling Technology 
 
 
Small molecule inhibitors 
Small molecule inhibitors were dissolved in DMSO and stored at -20oC, except tetracycline which 
was dissolved in water. 
Name 1o Target Concentration Source/ Citation 
AZ138 Eg5/KSP 1 µM AstraZeneca (Gascoigne and Taylor, 2008) 
AZ3146 Mps1 2 µM AstraZeneca (Hewitt et al., 2010) 
BI2536 Plk1 100 nM Boehringer Ingelheim (Steegmaier et al., 2007) 
GSK923295 Cenp-E 100 nM (Wood et al., 2010), (Bennett et al., in preparation) 
JQ1 Brd4 0.5 µM Stefan Knapp (Filippakopoulos et al., 2010) 
MLN8054 Aurora A 1 µM Millennium Pharmaceuticals (Manfredi et al., 2007) 
Nocodazole Microtubules 30 ng/ml Sigma 
Taxol Microtubules 100 nM Sigma 
Tetracycline Tet repressor See legends Sigma 
WEHI-539 Bcl-xL 100 nM Apexbio (Lessene et al., 2013) 
ZM447439  Aurora B 2 µM Tocris (Ditchfield et al., 2003) 	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